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TNF/cachectin has widespread effects in various tissues (1-6). Endothelium is an
importanttarget ofTHE Occupancy ofendothelial cellTNF receptors leads toacti-
vation of procoagulant function on the cell surface; to cell shape and cytoskeletal
modulation; and to alterations in other cell functions (1-6). Generalized, dissemi-
nated hemostatic abnormalitiesfollow infusion oflarger concentrations ofTNFinto
healthy animals(1-3, 6), but more localized activation ofcoagulant mechanisms might
well occurin particular microvascular beds in response to lower orlimiting concen-
trations ofthis cytokine in pathologic states. Onesuch target maybe the neovascula-
ture ofangiogenic tumors, whose vessels are under the influence of factors within
the tumormicroenvironment that potentially distinguishes theirendothelium from
that of other vascular beds.
Thestudies reported here demonstrate that suchaltered responses can beobserved
in the tumor vasculature in meth A sarcomas in mice, for within 30 min of TNF
infusion, fibrin formationoccurred throughout thetumorvascular bedincloserela-
tion to the endothelial cell surface and ultimately led to defective perfusion. In con-
trast, fibrin deposition and platelet aggregates were not observed in the normal vas-
culature. We haveshown that the altered stateofendotheliuminthe tumorvasculature
appears to be due, at least in part, to factor(s) elaborated by cultured meth A cells
thatenhance theprocoagulant response ofendotheliumtoTHE Thesefindingsprovide
a model system in which locally acting stimuli, by predisposing the endothelialcells
toprocoagulant response, cantarget the action ofacirculatingmediator toa partic-
ular vascular bed leading to selective thrombus formation.
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INTRAVASCULAR FIBRIN FORMATION IN METH A FIBROSARCOMAS
Materials and Methods
In Vioo Infusion and Morphologic Studies.
￿
For studies examing the effect of TNF on meth
A sarcomas in vivo, BALB/c mice were injected intradermally with meth A sarcoma cells
(105 cells/animal; generously provided by Drs. Hoffmann and Old, Memorial Sloan-
Kettering Cancer Center, NY [7]). After 7-10 d, when tumors reached a size of -1 cm in
diameter, animals were injected intravenously via a tail vein with TNF alone (3 wg/animal)
or TNF in the presence of either human fibrinogen (100 Rg/animal) or "'I-fibrinogen (7.5
wg/animal). Human TNF (-108 U/mg) was generously provided by BASF (Ludwigshafen,
Federal Republic of Germany), and this preparation was homogeneous on SDS-PAGE and
distinct from lymphotoxin, as described previously (8). TNF was heat inactivated as described
previously (8). Highly purified human fibrinogen, provided by Dr. J . Weitz (Hamilton Univer-
sity, Ontario, Canada), was radiolabeled by the lactoperoxidase method (9) (150 gCi/mg) and
migrated as three bands of unequal intensity on reduced SDS-PAGE corresponding to the
a, p, and y chains. At the indicated time after the TNF infusion, fibrin deposition/accumula-
tion of radioactivity in the tumor was assessed as follows. For morphologic studies, mice were
anesthetized and subjected to whole-body beating heart perfusion fixation (90-110 mm Hg).
Incorporation of radioactivity into the mouse tissue was determined after infusion of 125I-
fibrinogen by removing a piece of tissue, weighing it and, counting the sample in a gamma
counter. The presence of fibrin in tumor tissue was studied by excising tumor tissue, cutting
it up finely with a scalpel, and then extracting it with buffer containing Triton X-100 (2%)
and protease inhibitors (1.5 mM PMSF, 0.3 mM leupeptin, 20 ug/ml soybean trypsin inhib-
itor, 500 U/ml Trasylol). The extract was reacted with an equal volume of rabbit anti-mouse
IgG immunobeads (Bio-Rad Laboratories, Richmond, CA) for 2 h at 37°C to remove mouse
Ig. Control experiments in which a trace of radioiodinated mouse IgG was added to tissue
extracts indicated that 99% ofthe IgG was adsorbed by the beads. The extract was then made
9 M in urea and 10 mg/ml in dithiothreitol, boiled for 3 min, and added to an equal volume
of sample buffer for reduced Laemmli SDS-PAGE (10). After boiling for 3 min, the mixture
was centrifuged (10,000 RPM; 5 min), and the supernatant was subjected to SDS-PAGE (10%)
and Western blotting. In each case, the same amount of tumor tissue was processed and the
total protein loaded perlane ofthe gel was about the same. After Western blotting, nitrocellu-
lose membranes were reacted with mAb specific for human fibrin (11) followed by 1251-affinity-
purified goat anti-mouse IgG by the general method ofJohnson et al. (12) as described previ-
ously (13). The blot was then dried and exposed to Kodak X-Omat (XAR5) film (Eastman
Kodak Co., Rochester, NY) in the presence of a Cronex intensifying screen (Dupont Co.,
Wilmington, DE). Previous work has shown this antibody recognizes a polypeptide with M,
-59,000 after SDS-PAGE and Western blotting of fibrin-containing samples (14). Mice were
infused with human fibrinogen in these studies to visualize fibrin in the tumor bed, since
it appeared to show considerably greater immunoreactivity with the fibrin-specific mAb than
murine fibrin based on control studies under these conditions (also see Fig. 1 inset, lanes 2
and 3). Lack ofvisualization ofband(s) corresponding to the heavy and light chains of mouse
Igs (Fig. 1 inset, lanes 1 and 2) indicates that removal of mouse Ig using the above procedure
with anti-mouse IgG immunobeads was effective.
In certain experiments, mice were maintained on drinking water supplemented with the
warfarin derivative 3(a-acetonylbenzyl)-4-hydroxycoumarin (0.7 mg/1) for 3 d before the TNF
infusion (-7 d after the meth A cells were injected). Tumors grew to the same size in warfarin-
treated and control animals. Before carrying out an experiment with the anticoagulated animals,
a Factor X assay on the mouse plasma was performed (15). Only animals with Factor X levels
of <1% were used.
Cell Culture and Tissue Factor Assay.
￿
Endothelial cells derived from human umbilical cord
veins were prepared by the method ofJaffe (16) as modified by Thornton et al. (17) . Experi-
ments were carried within 24 h of the cells achieving confluence in 9.6-cm2 wells (passages
1-5). Cells were characterized as endothelial based on the presence ofvon Willebrand Factor
antigen (18), as described previously, and thrombomodulin activity (19). Meth A sarcoma
cells, provided by Drs. Hoffman and Old (Memorial Sloan-Kettering Cancer Center), were
grown in RPMI 1640 containing 10% FCS. Cultured medium was obtained from meth A
cells by placing them in serum-free medium (RPMI containing 10 mM HEPES, pH 7.4,NAWROTH ET AL .
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20 kg/ml transferrin, 10 ug/ml insulin, 1 gg/ml polymyxin B, and 5 mg/ml BSA) for 48 h .
Normal BALB/c mouse dermal fibroblasts were obtained from explant cultures of skin/sub-
cutaneous tissue . They were maintained and used to prepare conditioned medium as de-
scribed for meth A cells.
The tissue factor activity of endothelial cell monolayers was assayed using purified human
Factors VIIa (8 nM) (generously provided by Dr . R . Bach, Mount Sinai Medical School,
NY) andX (1.5 pM) in serum-free medium at 23°C . At 8 min, a sample (0.2 ml) of the
reaction mixture was removed and assayed for FactorXa activity by monitoring hydrolysis
of the chromogenic substrate benz-Ile-Glu-Gly-Arg-p-nitroanilide (20) . A mAb that blocks
human tissue factor coagulant activity was generously provided by Dr. R. Bach .
Results
When normal and tumor-bearing mice were infused with high concentrations of
TNF, 30 ltg/animal or more, most of the animals died with thrombi in multiple
organs, especially lung and liver, consistent with previous studies indicating the se-
vere toxicity of TNF at these concentrations (21, 22) . A TNF concentration of 10
ltg/animal resulted in less marked systemic toxicity and thrombus formation . At 3
gg/animal, most animals survived without gross lesions in the normal vasculature,
but hemorrhagic changes were observed in the tumors, indicating that this lower
dose ofTNFwas triggering hemostatic abnormalities in the vascular bed ofthe meth
A sarcoma, without widespread thrombohemorrhagic phenomena in other tissues .
Fibrin deposition in the tumor vasculature after infusion of TNF (3 gg/animal)
was assessed by measuring accumulation of radioactivity in the tumor in the pres-
ence of "'I-fibrinogen (Fig . 1) . About 10 times more radioactivity accumulated in
the tumor bed ofanimals coinfused with TNFthan in the meth A sarcomas ofsaline-
FIGURE 1 .
￿
Effect of TNF on the in-
corporation of fibrin/fibrinogen into
meth A sarcomas . Infusion of human
125I-fibrinogen : BALB/c mice bearing
meth A sarcomas were infused with
I'll-fibrinogen alone (O) or in the
presence ofTNF (') . At the indicated
times, tumor tissue was excised,
weighed, and counted . Other mice
were treated either with 3 (a-acetonyl-
benzyl)-4-hydroxycoumarin for3dbe-
foreTNF infusion ([-]), orwere infused
with heat-inactivated TNF (/) . Data
shown are themean andSEM oftripli-
cate determinations. (Inset) Infusion of
unlabeled fibrinogen followed by SDS
PAGE and Western blotting for a fibrin-specific epitope . Mice were infused with unlabeled human
fibrinogen in the presence or absence ofTNF 2 h after the TNF infusion, samples oftumor tissue were
then processed for reducedSDS-PAGE followed by Western blotting . Blots were reacted withmAb for
a fibrin-specific epitope, and the band(s) were visualized with a radiolabeled second antibody. (Lane
1) Tumor tissue from a mouse not infused with TNF or human fibrinogen ; (lane 2) tumor tissue from
a mouse infused with TNFbut nothuman fibrinogen ; (lane 3) tumor tissue from a mouse infused with
TNF andhuman fibrinogen; (lane 4) tumor tissue from a mouse treated with 3(a-acetonylbenzyl)-4-hy-
droxycoumarin and subsequently infused with TNF andhuman fibrinogen ; (lane 5) tumor tissue from
a mouse infused with heat-treated TNF and human fibrinogen ; (lane 6) tumor tissue from a mouse
infused with human fibrinogen alone . Details ofexperimental procedure are described in the text . The
majorband observed in lanes 3and 4 has an M, corresponding to -59 kD basedon interpolation from
semilogarithmic plots constructed from M, of standard proteins simultaneously .640
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TABLE I
Deposition of Radioactivity in Normal Mouse Tissues after Infusion of
1251fibrinogen in the Presence or Absence of TNF
BALB/c mice bearing meth A sarcomas were infused with 1251-fibrinogen alone
(contro0 or in the presence ofTNF (TNF) as described for Fig. 1 . After 1 h, the
indicated organ was excised, weighed, and counted. Data shown are the mean
and SEM of triplicates.
infused controls. In contrast, other organs showed only a minimal increase in up-
take of radioactivity after TNF infusion (Table I). Heat treatment of TNF, which
prevents its binding to cellular TNF receptors (8), prevented the enhanced deposi-
tion of radioactivity in the tumor bed, indicating that TNF was the active agent.
That activation of the coagulation mechanismwith fibrin formationwas responsible
for the accumulation of radioactivity in the tumors is implied by the decreased in-
corporationof radioactivityin tumors from anticoagulated animals. Consistent with
this hypothesis, after infusion of TNF, Western blots of tumor extracts (Fig. 1 inset)
reacted strongly with afibrin-specific mAb (Fig. 1 inset, lane 3). Treatment ofanimals
with 3(a-acetonylbenzyl)-4-hydroxycoumarinconsiderably attenuated this band, and
infusion of heat-treated TNF (in place of native TNF) prevented appearance of the
band corresponding to the fibrin-specific epitope (Fig. 1 inset, lanes 4 and 5).
These data indicate that activation ofthe coagulationmechanismleadingto fibrin
deposition in the tumorbedoccurs in response to theTNF infusion, and fibrin could
be visualized in the tumorvascular bed after TNF infusion (Fig. 2). In animals in-
fused with saline alone, there was no fibrin in the patent vessels of the tumors (Fig.
2, a and b). 30 min after the infusion of TNF, however, fibrin was visible within
the intravascular space closely associated with the endothelial surface (Fig. 2, c and
d). Fibrin was identified by the usual morphologic criteria (23), and the character-
istic ultrastructural periodicity of 21.0 nm (Fig. 2 e). The scanning electron micro-
graph (Fig. 2 c) demonstrates fibrin strands apposed to the luminal endothelial cell
surface, asituation neverobserved in control animals. Fibrin deposition was limited
to thevessels in the tumorbed. At theseearlytimes, adherenceof platelets andwhite
cells on thevessel wall didnotoccur, and platelet thrombiwere notseen in the spleen
or otherorgans. This is consistent with theoccurrence oflocalizedactivation ofcoagu-
lation within the tumor vasculature presumably initiated by endothelium. 2 h after
the TNF infusion, occlusive thrombi with a prominent fibrin component were ob-
served throughout the tumor (Fig. 2, fand ,g). Concomitant with the appearance
of these thrombi, unperfused areas were demonstrated in parallel studies carried out
with Evans blue to visualize blood flow. At earlier times, 1 h after TNF infusion,
unperfused areaswere focal, whereas 1-2hlater, largeareas, up to 80% ofthe tumor,
could not be reached by the dye. The presence of thrombi within the tumor vessels
Organ Control
1251
TNF
cpm/mg
Heart 30 ± 20 40 t 25
Lung 75 ± 40 180 ± 60
Skin 120 t 60 160 ± 50NAWROTH ET AL .
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FIGURE 2 .
￿
TNRinduced changes in tumor vasculature as a function oftime after injection . Mice
bearingmethA sarcomas were infused withTNFand subjected to perfusion fixation at the indi-
cated times . Light (a)and transmission (b) EM of tumors from saline-injected controls showing
patency of tumor vessels (a, arrowheads), which are delimitedby an intact luminal endothelium
(E in b) . Scanning (c) and transmission (d and e) EM 30 min after the injection ofTNF There
is evidence of fibrin (F) accumulation at the endothelial cell surface . Fibrin strands (in c) are
seen to be adherent to the endothelial cell surface and appear to exhibit direct endothelial cell
interactions (d) . The fibrin (both cell associated and inttaluminal) exhibits a characteristic 21-nm
periodicity (e) . Light (f) and transmission (g) EM 2 h after TNF injection . Large areas of the
tumorshowed extensive vascular accumulation of red cells (f) resulting from distal areas of vas-
cular thrombosis, one of which is delineated by brackets (g). Magnification : a, x600 ; b, x 6,000 ;
c,
￿
x 4,000 ; d, x 25,000 ; e, x 48,000 ; f, x 600 ; and g, x2,000 .
provides a potential link to in vitro studies demonstrating a procoagulant shift in
endothelial cell hemostatic properties (1-6).
Activation of coagulationwith fibrin formation afterthe infusion ofTNF was not
unexpected, based on the results of previous in vitro studies showing that TNFcould642
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induce modulation of endothelial cell coagulant properties to favor clotting (1-6).
However, the localization of fibrin deposition to the tumor vascular bed was unex-
pected. One mechanism that could account for localized clot formation in response
to TNF would be a vessel wall-dependent process accentuated in the tumor bed.
The diffusenature offibrin deposition in the tumorvascular bed and itsclose associ-
ationwith the endothelial cell surface supportedthehypothesis that atumor-endothelial
cell interaction might be involved. To examine this, supernatants of cultured meth
A sarcomacells (which hadno intrinsic procoagulant activity)generatedunder serum-
free conditions, were incubated with endothelial cell monolayers (Fig. 3 A) and in-
duction of tissue factor, a central initiator of coagulation (24), was examined. Ex-
posure ofcultured endothelium to tumor-conditioned medium alone led to at most
a small, probably insignificant, increase in procoagulant activity. TNF, at a sub-
maximal dose (0.1 nM), induced an increase in endothelial cell procoagulant ac-
tivity, as previously reported (4, 5) . Addition of dilutions of tumor-conditioned
medium, along with TNF, to endothelial cell cultures greatly increased the
procoagulant response in a dose-dependent manner. The procoagulant activity was
identified as tissue factor based on the Factor VIIa dependence of Factor X activa-
tion and the inhibitory effect of anti-tissue factor antibody (Fig. 3 A, darkened and
cross-hatched bars, respectively). Similarenhancement of tissue factor activity by tumor-
conditioned medium wasobserved at several TNFconcentrations. The experiments
in Fig. 3 involve exposure of endothelium to TNF and tumor-conditioned medium
for 7 h, sufficient time for themaximal procoagulant response to develop. Enhanced
tissue factor activity of endothelial cell monolayers was first noted at considerably
earliertimes. In contrast to the effect ofmedium derived from meth Acells, medium
conditioned by nontransformed BALB/c (the same strain from which the meth A
sarcoma was derived) fibroblasts had no effect on endothelial cell coagulant activity
in the presence or absence of THE
Preliminary characterization of the meth A-derived activity that augments the
procoagulant response of endothelium to TNF indicates that it was nondialyzable
(mol wt cut off; 3,500), heat sensitive (100°C for 10 min), and trypsin sensitive (50
leg for %2 h at 37°C). Gel filtration on Sephadex G150 (Fig. 3 B) demonstrated a
broad peak of activity corresponding to a mol wt range of N1-3 x 104. Although
the identity of the factor(s) responsible for the TNFenhancing effect of tumor-
conditioned medium is not clear, sensitivity to heat treatment and the presence of
polymyxinin all media(omission ofpolymyxinactually didnotinfluence theresults)
make endotoxin contamination unlikely to account for the observed changes in en-
dothelial cell TNF response. In this context, no IL-1, fibroblast growth factor, TNF,
IFN-1', or transforming growth factor a (TGF.)t activity2 was detectable in tumor-
conditioned medium. Since TGFO has been found in most mammalian tissues and
cell lines studied (31-33), it was important to determine whether TGFSi or TGF02
1 Abbreviation used in this paper: TGF, transforming growth factor.
2 IL-1 assays were carried out in the laboratory of Dr. P Lomedico, Hoffmann-LaRoche, Nutley,
NJ; fibroblast growth factor was assayed in the laboratory of Dr. Dan Rifkin, New York University,
New York, NY; TNF was assayed using the L cell assay (25) in our laboratory; IFN-y was assayed at
Hoffmann-LaRoche;transforming growth factorawasassayed in the laboratory of R. Derynk,Genen-
tech, San Francisco, CA.0
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FIGURE 3.
￿
Enhanced induction
of endothelial cell tissue factor
in response to TNFin thepres-
ence oftumor-conditioned me-
dium. (A)Conditioned medium
from meth A sarcoma cells at
the indicated dilution was incu-
bated with endothelial cells in
serum-free medium (RPMI
containing 10 mM Hepes, pH
7.4, 20 pg/ml transferrin, 10 pg/
ml insulin, 1 pg/ml polymyxin
B, and 5 mg/ml human serum
albumin). Cultures containedei-
ther serum-free medium alone
(0), TNF(0.1 nM)alone (TNF),
conditioned medium alone un-
diluted rns presence of conditioned medium
at the indicated dilution (TNF
+ Chi. Each addition wasin a volume of 10 pl and the volume of serum-free medium was 1 ml. After
7 h of incubation at 37°C, monolayers were washed, and fresh serum-free medium (0.5 ml) wasadded
along with Factors VIIa and/or X. After 8 min, the reaction was stopped and Factor Xa formation
was assessed. The cross-hatched bar corresponds to cultures exposed to tumor-conditioned medium
(Y2 dilution) in the presence of TNF followed by incubation for 1 h at 37°C with purified mAb (10
p/ml) to human tissue factor. Then, Factors VIla and X were added. Purified mouse IgG (10 ug/ml
and 100 pg/ml) had no effect on endothelial cell coagulant activity as measured in this assay. Thedar-
kened barcorresponds to cultures incubatedwith tumor-conditioned medium (Y2 dilution) in the pres-
ence of TNF in which the coagulant assay was carried out in the presence of only Factor X. Results
shown are the mean and SEMof triplicate determinations. Factor Xa generation was the same as un-
treatedcontrols when tumor-conditioned medium was addeddirectly to the Factor VIIa-X incubation
mixture in the absence of endothelial cells. (B)Tumor-conditioned medium (obtained as described in
A above) (I ml) was applied to a Sephadex G150 column (0.9 x 55 cm), eluted with 10 mM Hepes
(pH 7.4), 0.1 M NaCl, and fractions(1.3 ml)were collected. Aliquots of the indicatedcolumn fractions,
at a %4 dilution, were then incubated with endothelial cell monolayers in thepresence ofTNF (0.1 nM)
for 7 h at 37°C. The tissue factor assay was carried outas described above(A) and Factor Xa formed
over 7 min is shown(mean t SEM). TNFdenotes cells incubatedwith TNF alone(0.1 nM); B denotes
cells incubatedwith column buffer alone; and TNF + B denotes cells incubated with TNF (0.1 mM)
and column buffer. Column fractions 1-9were inactive in this assay. Thegel filtration columnwascalibrated
with standard proteins includingribonuclease (1.37 x 104), chymotrypsinogen A (2.5 x 104), OVA (4.3 x
104), and albumin (6.7 x 104).
had the capacity to enhance theendothelial cell procoagulant response to THE These
studies used human and porcine TGFp because of the availability of purified mate-
rial and the considerable sequence homology between TGF from different species
(murine, porcine, and human) (31-33). Neither TGFFi nor TGF02 (at concentra-
tions up to 500 pM) enhanced endothelial cell procoagulant activity in the presence
of TNF, suggesting that the activity in meth A culture supernatants was distinct
from TGFp.
- CM
(CM), or TNF in the
Discussion
Although thrombosis is a major cause of morbidity and mortality, mechanisms
involved in the pathogenesis of localized intravascular clot formation arelargely un-
characterized. Models ofintravascular clot formation in which rapid thrombus for-
mation occurs after contact of plasma factors and cellular elements of the blood644 INTRAVASCULAR FIBRIN FORMATION IN METH A FIBROSARCOMAS
with subendothelial cell components (26) present a picture of thrombosis in which
endothelial cell denudation is the critical initiating step. The results presented here
indicate that TNF, an endogenously produced mediator of the host response, can
selectively induce intravascularclot formationin thetumor vasculature ofmice bearing
meth A sarcomas in the presence of a viable endothelial monolayer and delineate
another model oflocalized thrombosis. Afterinfusion of TNF, radioiodinated fibrin-
ogen/fibrin accumulated in the tumor (Fig. 1) . The frank deposition of fibrin in the
tumor vascular bed (Fig. 1, inset and Fig. 2) indicates that activation of coagulation
with clot formation was clearly involved. In support of this hypothesis, coumadin,
an anticoagulant that prevents y-carboxylation of the vitamin K-dependent coagu-
lation proteins andthereby down regulates their effectiveinteraction with membrane
surfaces (27), considerably decreased accumulation of radiolabel and appearance
of the fibrin-specific epitope in the tumor bed. Furthermore, the intravascular local-
izationoffibrin deposition with evidence ofocclusivethrombi wasnotedin all animals
studied up to 2 h after the TNF infusion (Fig. 2). In contrast, neither consistent
focal uptake of 1251-fibrinogen/fibrin comparable in magnitude to that in the tumor
bed nor thrombus formation was seen in the normal vasculature of tumor-bearing
or normal mice. This indicates that the thrombogenic effects of TNF were being
targeted to the tumor vascular bed.
A central question that evolves from these studies concerns possible mechanisms
through which host andtumor-mediated processes couldlocally enhance the effects
of systemically infused TNF. Elaboration of cytokines/angiogenic agents and/or other
factors, such as changes in blood flow in the tumorbed, could certainlybe involved.
The experiments presented in Fig. 3 suggest that tumor cells elaborate a distinct
mediator(s) that potentiates the coagulant response of endothelium to TNF . Since
TNFhas been shown to induce ashiftin endothelial cell coagulantproperties favoring
activation of coagulation (1-6), enhancing this effect locally in a particular vascular
bed could constitute a potent thrombogenic stimulus. The mechanism(s) through
which tumor factor(s) modulate the response of endothelium to TNF remains un-
clear. Pilot studies examining the affinity and number of TNF binding sites on en-
dothelium after exposure to tumor-conditioned medium have not demonstrated a
change in the binding parameters of 1251TNF. This suggests that the effect of tumor
cell products on endothelial cell reactivity to TNF is mediated distal to ligand-receptor
interactions.
Locallyinduced clot formation, occurringrapidly(intiatedwithin 30 minof cytokine
infusion), is only one example of a focal TNF effect in tumors. By 4-8 h after TNF
infusion, tumor vessels are packed with leukocytic cells. Well-described toxic mor-
phologic changes in thetumor cells andhemorrhagicnecrosis also take place at later
times (21, 28). Some of these local changes, such as adhesion of leukocytes to en-
dothelium (29), may also be selectively enhanced in the tumorbed due to the effect
of factor(s) in the tumor microenvironment such as that which enhances the TNF
induced procoagulant response. Although the relationship between early activation
of coagulation in the tumor bed and tumor necrosis is unclear, pilot studies using
mice anticoagulated with the same coumadin compound used in these studies (as
described forthe experiment in Fig. 1) have shown attenuated tumornecrosis, based
on reduction in tumorweight, by as much as 50% in anticoagulated compared with
control mice. In this context, selectivedeposition offibrin, awell-recognized stimu-NAWROTH ET AL.
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lant of theinflammatory response (30), in thetumorbedcouldbe afactor promoting
subsequent leukocytic infiltration. Further studies with a variety of anticoagulants
and tumors will be required to gain further insight into this issue.
The studiespresented in this report indicate that intravascular clot formationwithin
the tumor vasculature is part of the early response of meth A sarcomas to TNF .
Thelocalization ofclot formation to the tumorbedprovides apotentially important
model for examining mechanisms underlying intravascular thrombus formation.
Summary
Recent studieshave indicated that TNFcanpromote activation of thecoagulation
mechanism by modulating coagulant properties of endothelial cells. In this report,
we demonstrate that infusion oflow concentrations of TNF (3 wg/animal) into mice
bearing meth A fibrosarcomas leads to localized fibrin deposition with formation
of occlusive intravascular thrombi in close association with the endothelial cell sur-
face. Studies with 1251-fibrinogen showed tenfold enhanced accumulation of radio-
activity in tumor within 2 h after TNF infusion. Western blots of tumor extracts
subjected to SDS-PAGE and visualized with a fibrin-specific mAb indicated that
fibrin forms in thetumor aftertheTNFinfusion. Electron microscopicstudiesdemon-
strated fibrin strands, based on the characteristic 21-nm periodicity, whichappeared
to be adherent to the endothelial cell surface. Further ultrastructural studies indi-
cated that fibrin formation, first evident within 30 min of the TNF infusion, led
to occlusivethrombi limited to the tumorvascular bed (i.e., notin thenormal mouse
vasculature) within 2 h and was associated with an 80% reduction in tumor perfu-
sion based on studies with Evans blue. In view of previous work concerning TNF
induction of endothelial cell procoagulant activity, the hypothesis that tumor cell
products prime the response of endothelium to this cytokine was tested. Superna-
tants of cultured meth A fibrosarcomas obtained serum-free conditions, which had
no intrinsic procoagulant activity, considerably enhanced tissue factor induction in
endothelium in response to submaximal concentrations of TNF The factor(s) in
the tumor-conditioned medium appeared to be distinct from IL-1, fibroblast growth
factor, IFN-7, TNF, endotoxin, TGFa, and TGFR. These studies delineate a novel
model of localized clot formation in which thrombosis is initiatedby a pathophysio-
logic mediator, TNF, and provides an opportunity to examine mechanisms in the
microenvironment directing clot formation to the tumor vascular bed.
We gratefully acknowledge helpful discussions with Drs. Cerami, Esmon, andGodman during
the course of these studies.
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